HC Wainwright Lowers Savara (NASDAQ:SVRA) Price Target to $6.00

Savara (NASDAQ:SVRA) had its price target decreased by stock analysts at HC Wainwright from $10.00 to $6.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 88.09% from the company’s current price. HC Wainwright also issued estimates for Savara’s Q4 2024 earnings at ($0.11) EPS, FY2024 earnings at ($0.46) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.44) EPS, FY2027 earnings at ($0.25) EPS and FY2028 earnings at $0.00 EPS.

A number of other analysts have also issued reports on SVRA. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price target on shares of Savara in a research note on Tuesday, October 1st. Evercore ISI reaffirmed an “in-line” rating and issued a $5.00 price target (down from $7.00) on shares of Savara in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.17.

Savara Stock Down 1.8 %

Shares of SVRA opened at $3.19 on Wednesday. The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26. Savara has a 12 month low of $3.09 and a 12 month high of $5.70. The stock’s 50 day moving average is $3.93 and its two-hundred day moving average is $4.21. The firm has a market cap of $525.08 million, a P/E ratio of -7.42 and a beta of 1.02.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). Analysts predict that Savara will post -0.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. ProShare Advisors LLC raised its holdings in shares of Savara by 9.0% in the 1st quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock valued at $128,000 after buying an additional 2,114 shares during the period. The Manufacturers Life Insurance Company grew its stake in Savara by 9.0% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company’s stock worth $191,000 after purchasing an additional 3,706 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Savara by 15.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock worth $168,000 after acquiring an additional 4,625 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Savara by 14.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 41,250 shares of the company’s stock worth $166,000 after acquiring an additional 5,335 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Savara by 5.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company’s stock worth $533,000 after acquiring an additional 6,141 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.